Metformin

Metformin has been studied in 2,400 papers since 1984: 220 trials and 503 observational studies in people, 599 in animals, 206 in cells, 768 reviews; 962 in the past year. It is an approved medicine. The newest paper, Nov 16, 2026: “Efficacy and Safety of Anagliptin Added to Metformin and Empagliflozin 10 mg in Korean Adults With Type 2 Diabetes:…”.

InterventionBiguanidesApproved 1995

2,400 papers study it382 more mention it3,113 findingsUpdated

PubChemChEBIMeSH

Research on it is growing 26% faster than aging research as a whole: 111 papers in the latest year counted

Part of Bryan Johnson's Blueprint and David Sinclair's daily regimen in Lifespan

209 new papers in 30 daysSee all 2,747 papers on metformin

At a glance

Independent labs found the same change in cells, worms or flies, mice and people. 573 independent labs in 69 countries; 1,170 trials, 140 about aging, 502 with no results posted.

“Randomization to metformin was associated with higher odds of progression to high ABI (adjusted OR=1.35, 95% CI 1.04-1.77, p=0.027) relative to placebo”
Long-Term Effects of Metformin and Lifestyle Interventions on Ankle-Brachial Index in the Diabetes Prevention Program Outcomes Study (DPPOS)ADA Scientific Sessions 2026 abstract2026doi:10.2337/db26-1418-p

263 of its findings point the other way.

Cells, worms or flies, mice and humans: replicated by independent labs.
  • 573 independent labs in 69 countries
  • 263 findings against
  • 1,170 trials, 140 about aging, 502 with no results posted
  • Funders: National Institutes of Health and others
  • 181 of 2,682 findings with company ties
  • 38 of 1,170 trials sponsored by its developers
  • Human trial219
  • Humans496
  • Animals535
  • Model organisms53
  • Cells198
  • In silico43

146 studies gave metformin to people and measured what changed.

What changedDesignPeopleSource

no change: Has no effect on body weight

Randomized trial8 weeks38 peopleWomen25–35 yearsAdjunctive to a very-low-carbohydrate, low-calorie, high-protein diet in overweight or obese women with PMOS; baseline-adjusted comparisonNutrition journal, Nov 12, 2026

no change: Has no effect on total prolactin45.85 ± 5.06 to 45.00 ± 5.04 ng/mL

Trial6 months120 peopleWomenPCOS; before-and-after comparison without an untreated comparatorPathophysiology : the official journal of the International Society for Pathophysiology, Nov 10, 2026

up: Improves composite glycemic outcomeWin ratio 1.46 (95% CI 1.13–1.89); net treatment benefit 13.7 percentage points (95% CI 4.3–22.8)

Randomized trialFollow-up through 12 weeks postpartum526 peopleMean 34.4 years (SD 4.8)Gestational diabetes; early initiation plus usual care versus placebo plus usual careJAMA network open, Nov 3, 2026

down: Decreases body weight−2.0 kg from baseline

down: Decreases HbA1c

Randomized trial6 months217 people30–70 yearsMidlife adults; Older adults; Prediabetes and body mass index ≥23 kg/m2; change from baselineDiabetes & metabolism journal, Nov 1, 2026

up: Improves systemic insulin sensitivity

down: Protects against regional brain glucose uptake decline

Randomized trial40 weeks40 peopleolder adultsOlder adults; insulin resistanceThe Journal of clinical investigation, Oct 27, 2026

What did mouse lifespan tests of metformin find?

NIA ITP

The NIA Interventions Testing Program ran 1 arm in 2011; the change in median lifespan ran from 0% to +7%.

What did other lifespan studies of metformin find?

DrugAge

DrugAge records 52 results from 15 papers: 21 in D. melanogaster, 20 in C. elegans, 7 in mice and 3 other species. Average lifespan is the mean or the median, as each paper reports it.

What did studies of metformin find?

443

Studies of metformin measured 443 outcomes; the most studied are inflammation (22 studies), cellular senescence (16) and AMPK signaling (15).

Inflammation

downin reviews8downin human cells4downin rats4downin mice3+3

22 studies
  1. Metformin decreases inflammation in the L4-6 SDH of DM rats.

    “metformin intervention reduced the activation levels of microglia and astrocytes in the L4-6 SDH of DM rats”

    Animalsin the L4-6 SDH of DM ratsspinal dorsal horn

    Mechanism by which metformin alleviates neuralgia in the spinal cord of diabetic rats

    Neuroscience

  2. Metformin decreases inflammation in human cells (cells from healthy donors).

    “it exerted both anti-inflammatory and anti-autophagic effects on these cells, as evidenced by downregulation of IL-6 and MAPLC3 expression”

    Cellscells from healthy donorsnormal colonocytes

    Effects of metformin on cell viability and inflammatory status of human colonocytes: an in vitro preliminary analysis

    Reports of practical oncology and radiotherapy : journal of Greatpoland Cancer Center in Poznan and Polish Society of Radiation Oncology

  3. Metformin decreases inflammation.

    “the reduction of oxidative stress and inflammatory mediators”

    Reviewarticular cartilage

    Exploring the therapeutic applications of metformin in articular cartilage repair: mechanistic insights and translational perspectives

    Frontiers in immunology

  4. Metformin decreases inflammation in ICV-STZ-treated rats.

    “suppressed TNF-α, IL-1β, and iNOS expression”

    Animalsin ICV-STZ-treated ratshippocampus2 g/L12 weeksmales

    Hippocampal Klotho expression is associated with the neuroprotective effects of metformin against ICV-STZ-induced cognitive deficits

    European journal of pharmacology

  5. Metformin decreases inflammation (as reported in studies cited by the review).

    “metformin suppresses neuroinflammation by inhibiting the NF-κB signaling pathway and the NLRP3 inflammasome”

    Reviewas reported in studies cited by the review

    Metformin in Neurodegenerative Diseases: Mechanisms and Therapeutic Implications

    Current neuropharmacology

  6. Metformin decreases inflammation in rats (LPS-induced).

    “attenuating LPS-induced oxidative stress and inflammatory damage in placental tissue and trophoblast cells.”

    AnimalsLPS-inducedplacentafemales

    Combined treatment with metformin and melatonin improves placental mitochondrial function via the AMPK/SIRT3 pathway in an LPS-induced model of preeclampsia

    European journal of pharmacology

  7. Metformin decreases inflammation.

    “Metabolic modulators such as metformin and rapamycin attenuate inflammatory signaling”

    Review

    Inflammaging: Experimental Insights and Translational Advances

    European journal of immunology

  8. Metformin decreases inflammation.

    “exhibiting several properties, including antioxidant, anti-inflammatory, and anti-apoptotic effects across various tissues”

    Reviewvarious tissues

    Mechanistic Insights into metformin's neuroprotective effects against drug-induced neurotoxicity

    Metabolic brain disease

  9. Metformin decreases inflammation (preliminary findings, context-dependent).

    “metformin may modulate microbial fitness, attenuate excessive inflammation, and influence bone remodeling”

    Reviewpreliminary findings, context-dependent

    Metformin as a Metabolic Reprogramming Interface in Host-Pathogen and Bone Microenvironment Crosstalk: A Dual-Target Strategy Against Antimicrobial Resistance and Osteoporotic Bone Loss

    Antibiotics (Basel, Switzerland)

  10. Metformin decreases inflammation in human cells under Ang II challenge (near-baseline levels).

    “Metformin markedly suppressed these responses, reducing cytokine expression toward near-baseline levels”

    Cellsunder Ang II challengeheart

    Metformin Attenuates Angiotensin II-Induced Cardiac Inflammaging-Like Injury Through Coordinated Nrf2 Activation and NF-κB Suppression

    Iranian journal of pharmaceutical research : IJPR

All 22

More on Inflammation

Cellular senescence

downin human cells5downin cells4downin mice3downin C. porcellus1+3

16 studies
  1. Metformin decreases cellular senescence in human cells (late-passage and D-galactose-treated THESCs).

    “Metformin significantly restored cell proliferation, reduced senescence markers (P16, P21), and alleviated mitochondrial dysfunction and oxidative stress in late-passage and D-galactose-treated THESCs.”

    Cellslate-passage and D-galactose-treated THESCshuman endometrial stromal cells

    Functional contribution of TERT to mitigation of endometrial stromal cell senescence by metformin through modulation of the AKT/mTOR axis

    European journal of pharmacology

  2. Metformin decreases cellular senescence in human cells (hyperosmotic stress; metformin pretreatment).

    “In vitro, metformin pretreatment significantly attenuated hyperosmolarity-induced cell death, ROS accumulation, and the expression of senescence and inflammatory markers.”

    Cellshyperosmotic stress; metformin pretreatmenthuman corneal epithelial cells

    Metformin alleviates dry eye-associated corneal epithelial senescence and oxidative stress via AMPK activation

    Experimental eye research

  3. Metformin decreases cellular senescence in human cells (hydrogen peroxide- and high-glucose/high-lipid-induced senescence).

    “metformin treatment effectively attenuated hydrogen peroxide- and high-glucose/high-lipid-induced fibroblast senescence in vitro”

    Cellshydrogen peroxide- and high-glucose/high-lipid-induced senescencefibroblast

    Artery disease and diabetic foot ulcers share gene-activity patterns

    Research SquarePreprint

  4. Metformin decreases cellular senescence in human cells (ACS patient-derived cells).

    “Treatment with metformin or SRT1720 partially reversed the senescent and dysfunctional phenotype, improving metabolic and functional readouts.”

    CellsACS patient-derived cellsiPSC-derived endothelial cell

    iPSC-derived endothelial cells from ACS patients show mitochondrial dysfunction and premature senescence

    ESC Congress 2026 abstract

  5. Metformin decreases cellular senescence in mice (combined with PLA/nHA scaffold in aged femoral defects).

    “In aged femoral defects, PLA/nHA/metformin reduced local senescence and accelerated new bone formation”

    Animalscombined with PLA/nHA scaffold in aged femoral defectsfemur

    Scaffold and metformin sped new bone formation in aged mice

    Nano Research

  6. Metformin decreases cellular senescence in human cells (tert-butyl hydroperoxide-exposed NP-MSCs).

    “In NP-MSCs exposed to tert-butyl hydroperoxide, metformin increased AMPK phosphorylation and SIRT1 expression, enhanced UPRmt signaling, and reduced apoptosis and senescence.”

    Cellstert-butyl hydroperoxide-exposed NP-MSCsnucleus pulposus

    Metformin activates the mitochondrial unfolded protein response via the AMPK/SIRT1 pathway to delay intervertebral disc degeneration

    Free radical biology & medicine

  7. Metformin decreases cellular senescence in cells (TGF-β-induced).

    “Metformin significantly attenuated transforming growth factor-β (TGF-β)-induced cardiac fibroblast activation and the associated senescence-like phenotype.”

    CellsTGF-β-induced

    Metformin Inhibits Cardiac Fibroblast Differentiation by Promoting Fatty Acid β-Oxidation: Implications for Age-Associated Cardiac Fibrosis

    Cells

  8. Metformin decreases cellular senescence in pigs (Ang II-induced, measured as P21 expression).

    “reduced Ang II-induced expression of matrix remodelling (MMP1, MMP2) and senescence (P21) markers”

    AnimalsAng II-induced, measured as P21 expressioncoronary artery

    AMPK-mediated prevention of vascular dysfunction with metformin: Experimental and population-based evidence

    British journal of pharmacology

  9. Metformin decreases cellular senescence in D-galactose-induced CM aging model.

    “MET significantly attenuated D-galactose-induced senescence in CM tissue and primary CSMCs”

    Animalsin D-galactose-induced CM aging model

    Metformin Attenuates Ciliary Muscle Aging by Downregulating GSK-3β to Modulate Cell-Cycle Progression and Autophagy

    FASEB journal : official publication of the Federation of American Societies for Experimental Biology

  10. Metformin decreases cellular senescence in H2O2-treated cells.

    “Metformin pretreatment significantly reduced H2O2-induced senescent cell number.”

    Cellsin H2O2-treated cellsevery 72 h

    Metformin Attenuates Oxidative Stress-Induced Premature Senescence and Neuroinflammation in Primary Astrocyte Cultures

    Cell and Tissue Biology

All 16

More on Cellular senescence

AMPK signaling

upin reviews8upin rats3upin human cells1upin humans1+2

15 studies
  1. Metformin activates AMPK signaling in the L4-6 SDH of DM rats.

    “Metformin intervention significantly elevated the levels of phosphorylated-AMPK (p-AMPK, the activated form of AMPK) in the L4-6 spinal dorsal horn (SDH) of DM rats.”

    Animalsin the L4-6 SDH of DM ratsspinal dorsal horn

    Mechanism by which metformin alleviates neuralgia in the spinal cord of diabetic rats

    Neuroscience

  2. Metformin activates AMPK signaling.

    “For instance, metformin activates AMPK, inhibiting mTOR and promoting apoptosis”

    Review

    Type 2 diabetes medications and their implications for cancer treatment: A comprehensive review

    Molecular aspects of medicine

  3. Metformin activates AMPK signaling (Narrative synthesis of metformin, SGLT2 inhibitors, and intermittent fasting).

    “We delineate molecular convergence on adenosine monophosphate kinase (AMPK) activation”

    ReviewNarrative synthesis of metformin, SGLT2 inhibitors, and intermittent fasting

    Metformin, SGLT2 Inhibitors, and Intermittent Fasting: Convergent Pathways to Healthspan Extension, Cardiovascular Longevity, and Cancer Prevention-A Narrative Review

    Current issues in molecular biology

  4. Metformin activates AMPK signaling in rat cells (diabetic erectile dysfunction model).

    “Mechanistically, DMBG activated AMPK and inhibited mTOR phosphorylation in PCECs, increasing eNOS.”

    Cellsdiabetic erectile dysfunction modelprimary cavernosal endothelial cells

    Metformin (DMBG) ameliorates diabetic erectile dysfunction via the AMPK/mTOR pathway in association with endothelial autophagy reactivation

    Journal of reproductive immunology

  5. Metformin activates AMPK signaling.

    “It acts by activating the AMPK, which leads to a cascade of downstream events such as the inhibition of mTOR, increased mitochondrial biogenesis, and autophagy”

    Review

    Metformin at the convergence of aging and longevity

    Aging

  6. Metformin activates AMPK signaling.

    “metformin may confer cardiovascular benefits through activation of AMP-activated protein kinase”

    Review

    Metformin: A Promising Candidate for Slowing the Progression of Cardiovascular Aging

    Aging and disease

  7. Metformin activates AMPK signaling in LPS-induced preeclampsia model.

    “Both MEL and MET individually activated the AMPK/SIRT3 signaling pathway, thereby enhancing mitochondrial function and placental energy homeostasis”

    Animalsin LPS-induced preeclampsia modelplacentafemales

    Combined treatment with metformin and melatonin improves placental mitochondrial function via the AMPK/SIRT3 pathway in an LPS-induced model of preeclampsia

    European journal of pharmacology

  8. Metformin activates AMPK signaling.

    “achieves mTOR suppression, AMPK activation, and downstream anti-proliferative effects through an overlapping molecular pathway”

    Review

    Mechanistic Review — Metformin as a Caloric Restriction Mimetic in Helminth-Endemic Populations

    Zenodo (CERN European Organization for Nuclear Research)Preprint

  9. Metformin activates AMPK signaling in mice.

    “metformin activated AMP-activated protein kinase (AMPK)”

    Animalslung

    B77-21 Senomorphic Effects of Metformin Promotes Resolution of Age-Associated Lung Fibrosis

    American Journal of Respiratory and Critical Care Medicine

  10. Metformin activates AMPK signaling.

    “Metformin activates AMPK, improving mitochondrial function and reducing oxidative stress in neurons.”

    Reviewneuron

    Metformin for Diabetes-Associated Cognitive Decline

    Zenodo (CERN European Organization for Nuclear Research)Preprint

All 15

More on AMPK signaling

Oxidative stress and ROS signaling

downin reviews5downin human cells4downin cells1upin human cells1+3

13 studies
  1. Metformin decreases oxidative stress and ROS signaling in human cells (late-passage and D-galactose-treated THESCs).

    “Metformin significantly restored cell proliferation, reduced senescence markers (P16, P21), and alleviated mitochondrial dysfunction and oxidative stress in late-passage and D-galactose-treated THESCs.”

    Cellslate-passage and D-galactose-treated THESCshuman endometrial stromal cells

    Functional contribution of TERT to mitigation of endometrial stromal cell senescence by metformin through modulation of the AKT/mTOR axis

    European journal of pharmacology

  2. Metformin decreases oxidative stress and ROS signaling in rats (cisplatin-induced acute kidney injury).

    “Treatment with metformin or intermittent fasting significantly improved renal function tests, reduced oxidative stress”

    Animalscisplatin-induced acute kidney injurykidney200 mg/kg12 daysmales

    Comparison between metformin and intermittent fasting for renoprotective effects through mitophagy modulation in a rat cisplatin-induced acute kidney injury model

    Scientific reports

  3. Metformin increases oxidative stress and ROS signaling in human cells.

    “increased mitochondrial mass and mitochondrial ROS (mtROS) production.”

    CellsPBMCs20 mM24 hours

    Metformin promotes the expansion of CD8+ central memory T cells by offsetting Pentose phosphate pathway

    Research SquarePreprint

  4. Metformin decreases oxidative stress and ROS signaling in humans (obesity).

    “These approaches improve glycemic control, reduce inflammation and oxidative stress, enhance endothelial function, and contribute to cardiovascular protection.”

    Reviewobesity

    Endothelial Dysfunction and Obesity: New Diagnostic and Therapeutic Strategies

    International journal of molecular sciences

  5. Metformin decreases oxidative stress and ROS signaling (preclinical work).

    “Preclinical work suggests these pathways enhance mitochondrial biogenesis, reduce oxidative stress”

    Reviewpreclinical work

    Metformin: A Promising Candidate for Slowing the Progression of Cardiovascular Aging

    Aging and disease

  6. Metformin decreases oxidative stress and ROS signaling.

    “exhibiting several properties, including antioxidant, anti-inflammatory, and anti-apoptotic effects across various tissues”

    Reviewvarious tissues

    Mechanistic Insights into metformin's neuroprotective effects against drug-induced neurotoxicity

    Metabolic brain disease

  7. Metformin decreases oxidative stress and ROS signaling in H2O2-induced senescent HUVECs.

    “metformin regulated mitochondrial dynamics, restored mitochondrial membrane potential, and attenuated intracellular oxidative stress”

    Cellsin H2O2-induced senescent HUVECs

    Metformin Alleviates Stress-Induced Premature Senescence of Vascular Endothelial Cells by Regulating Mitocytosis

    International journal of molecular sciences

  8. Metformin decreases oxidative stress and ROS signaling in human cells under Ang II challenge (120.0 ± 2.0% vs 187.7 ± 2.5% of control).

    “lowering ROS to 120.0 ± 2.0%, decreasing the BAX/BCL-2 ratio from 2.98 to 1.19, and reducing cleaved caspase-3 and cleaved PARP to 120% and 112% of control, respectively.”

    Cellsunder Ang II challengeheart

    Metformin Attenuates Angiotensin II-Induced Cardiac Inflammaging-Like Injury Through Coordinated Nrf2 Activation and NF-κB Suppression

    Iranian journal of pharmaceutical research : IJPR

  9. Metformin decreases oxidative stress and ROS signaling in H2O2-treated cells.

    “H2O2–induced increase in levels of p53, p21WAF1, IL-6, CXCL1, and CCL2 mRNA and ROS was significantly inhibited by metformin.”

    Cellsin H2O2-treated cellsevery 72 h

    Metformin Attenuates Oxidative Stress-Induced Premature Senescence and Neuroinflammation in Primary Astrocyte Cultures

    Cell and Tissue Biology

  10. Metformin decreases oxidative stress and ROS signaling.

    “Metformin activates AMPK, improving mitochondrial function and reducing oxidative stress in neurons.”

    Reviewneuron

    Metformin for Diabetes-Associated Cognitive Decline

    Zenodo (CERN European Organization for Nuclear Research)Preprint

All 14

More on Oxidative stress and ROS signaling

Autophagy

upin cells3upin rats2upin C. porcellus cells1downin human cells1+3

10 studies
  1. Metformin activates autophagy in rats (MCAO/R rats).

    “Met activated the AMPK/mTOR pathway and promoted autophagic flux in hippocampal tissue”

    AnimalsMCAO/R ratshippocampus

    Metformin regulates astrocyte autophagy via the AMPK/mTOR pathway to improve glutamate homeostasis and prevent cognitive impairment induced by cerebral ischemia-reperfusion

    Frontiers in pharmacology

  2. Metformin inhibits autophagy in human cells (cells from healthy donors).

    “it exerted both anti-inflammatory and anti-autophagic effects on these cells, as evidenced by downregulation of IL-6 and MAPLC3 expression”

    Cellscells from healthy donorsnormal colonocytes

    Effects of metformin on cell viability and inflammatory status of human colonocytes: an in vitro preliminary analysis

    Reports of practical oncology and radiotherapy : journal of Greatpoland Cancer Center in Poznan and Polish Society of Radiation Oncology

  3. Metformin improves autophagy in cells (MMAE-ADC-associated stress).

    “Metformin improved lysosomal and autophagy-associated readouts”

    CellsMMAE-ADC-associated stressmacrophage

    PLA2G4A-Associated macrophage lysosomal stress contributes to MMAE-ADC-induced peripheral neuropathy

    Journal of neuroinflammation

  4. Metformin activates autophagy in rats (streptozotocin-induced diabetic erectile dysfunction).

    “It downregulated elevated serum VEGF-A and upregulated impaired penile autophagy markers (LC3-II, BECLIN1, ATG5).”

    Animalsstreptozotocin-induced diabetic erectile dysfunctionpenis30 days

    Metformin (DMBG) ameliorates diabetic erectile dysfunction via the AMPK/mTOR pathway in association with endothelial autophagy reactivation

    Journal of reproductive immunology

  5. Metformin activates autophagy.

    “the activation of AMPK/SIRT1-mediated autophagy”

    Reviewarticular cartilage

    Exploring the therapeutic applications of metformin in articular cartilage repair: mechanistic insights and translational perspectives

    Frontiers in immunology

  6. Metformin increases autophagy in human cells (chromosome 21 trisomy).

    “including attenuation of mTOR-associated signaling, enhancement of autophagic flux and normalization of mitophagy-related protein levels”

    Cellschromosome 21 trisomyfibroblast

    Metformin improves mitophagy-related pathways and mitochondrial-lysosomal homeostasis in chromosome 21 trisomic fibroblasts

    Cellular and molecular life sciences : CMLS

  7. Metformin activates autophagy in senescent macrophages in the inflammaging microenvironment.

    “The released metformin restores intracellular homeostasis by enhancing autophagy”

    Cellsin senescent macrophages in the inflammaging microenvironmentreleased from implant

    Recasting Inflammaging into Regeneration

    Rare Metals

  8. Metformin increases autophagy in senescent macrophages (about 1-fold higher autophagosome fluorescence).

    “0.1 mM metformin restored S‐MΦ homeostasis by enhancing autophagy (about 1‐fold higher autophagosome fluorescence)”

    Cellsin senescent macrophages0.1 mM

    Targeting Inflammaging: A Metformin‐Releasing Titanium Implant Reprograms Senescent Macrophages to Orchestrate Angiogenesis and Osteogenesis

    Rare Metals

  9. Metformin activates autophagy in rat cells (compared with the control group).

    “autophagy (Beclin-1↑, LC3-II/-I ratio↑, P62↓) and an inhibition of autophagy (LC3↓) in testicular organoids after treatment with Met and HCQ, respectively”

    Cellscompared with the control grouptesticular organoid5 μM7 days

    Autophagy Modulation Influenced the Spermatogenesis in Rodent Testicular Organoids and Diabetic Condition

    Advanced pharmaceutical bulletin

  10. Metformin increases autophagy in aged CSMCs.

    “In addition, MET restored autophagic activity in aged CSMCs and helped maintain intracellular and mitochondrial homeostasis.”

    Cellsin aged CSMCs

    Metformin Attenuates Ciliary Muscle Aging by Downregulating GSK-3β to Modulate Cell-Cycle Progression and Autophagy

    FASEB journal : official publication of the Federation of American Societies for Experimental Biology

More on Autophagy

Body weight

downin humans6no changein humans1upin rats1

8 studies
  1. Metformin showed no clear effect on body weight in humans.

    “no significant between-group differences in any outcome after adjustment.”

    Human trialAdjunctive to a very-low-carbohydrate, low-calorie, high-protein diet in overweight or obese women with PMOS; baseline-adjusted comparison8 weeksfemalesn = 38

    Clinical and multiomics changes with or without metformin during an 8-week very-low-carbohydrate intervention in PMOS patients: an exploratory randomized controlled trial

    Nutrition journal

  2. Metformin decreases body weight in humans (Prediabetes and body mass index ≥23 kg/m2; change from baseline) (−2.0 kg from baseline).

    “all groups showed significant weight reduction (−0.7 kg STM, −2.3 kg LSM, −2.0 kg MET; P<0.001).”

    Human trialPrediabetes and body mass index ≥23 kg/m2; change from baseline6 monthsn = 217

    Effects of a 6-Month Intervention on Body Weight and Cardiometabolic Parameters Based on the Korean Diabetes Prevention Study

    Diabetes & metabolism journal

  3. Metformin decreases body weight in humans (-5.7±5.2 vs. -2.3±5.4 kg).

    “Metformin led to more weight loss than placebo (-5.7±5.2 vs . -2.3±5.4 kg, p=0.0002)”

    Human trialtwo yearsn = 145

    A Randomized Clinical Trial of Metformin to Reduce Frailty in Older Adults with Glucose Intolerance

    medRxiv : the preprint server for health sciencesPreprint

  4. Metformin decreases body weight in humans (net weight loss, p<0.005).

    “MET led to a net weight loss (p<0.005)”

    Human trial2 yearsn = 15

    Long-Term Impact of Early Oral Antidiabetic Therapy on Insulin Secretion Phases in Individuals with Prediabetes (PreDM): Insights from Hyperglycemic Clamp Studies

    ADA Scientific Sessions 2026 abstract

  5. Metformin is linked with lower body weight in humans (add-on therapy) (36.9% (79/214) lost ≥5% of baseline weight).

    “79/214 (36.9%) with add-on metformin”

    Humansadd-on therapy12 monthsn = 214

    Effectiveness of a Psychiatrist-Led Clinic for Metabolic Health in Severe Mental Illness: A Retrospective Chart Review Study

    Acta psychiatrica Scandinavica

  6. Metformin decreases body weight in humans (MD -3.86 kg (95% CI -5.02 to -2.70)).

    “metformin (MD, -3.86 kg; 95% CI, -5.02 to -2.70; k = 16; moderate certainty)”

    Reviewin antipsychotic-treated patients with schizophrenia spectrum disorders, versus placebo or standard care

    Pharmacological Interventions for Weight Reduction in Patients With Schizophrenia Treated With Antipsychotics: A Systematic Review and Network Meta-Analysis

    JAMA psychiatry

  7. Metformin decreases body weight in PMOS.

    “Metformin is associated with modest reductions in body weight and improves metabolic and anthropometric outcomes.”

    Reviewin PMOS

    Pharmacological treatment of polyendocrine metabolic ovarian syndrome in adults

    Drug and therapeutics bulletin

  8. Metformin increases body weight in high-fat diet and STZ-induced T2DM rats.

    “All treated groups showed significantly higher body weights than DC, indicating protection against STZ-induced weight loss.”

    Animalsin high-fat diet and STZ-induced T2DM rats28 daysmalesn = 30

    Antidiabetic effects of Gymnema sylvestre and metformin co-therapy in a type 2 diabetic rat model

    World journal of experimental medicine

Cell viability

upin human cells3no changein human cells2downin human cells1downin rat cells1+1+106%

7 studies
  1. Metformin showed no clear effect on cell viability in human cells (cells from healthy donors).

    “Metformin did not affect the viability of normal colonocytes.”

    Cellscells from healthy donorsnormal colonocytes

    Effects of metformin on cell viability and inflammatory status of human colonocytes: an in vitro preliminary analysis

    Reports of practical oncology and radiotherapy : journal of Greatpoland Cancer Center in Poznan and Polish Society of Radiation Oncology

  2. Metformin showed no clear effect on cell viability in human cells (cisplatin exposure).

    “While Met did not significantly reduce SA-β-gal activity or restore cell viability”

    Cellscisplatin exposureinduced pluripotent stem cell-derived motor neurons

    Metformin Partially Modulates Cisplatin-Induced Neuronal Senescence but Does Not Prevent Rat Peripheral Sensory Hypersensitivity

    Toxicology mechanisms and methods

  3. Metformin increases cell viability in human cells (106.30%).

    “The 100 μM dose significantly maximized cell viability (106.30%) and clonogenicity”

    Cells100 μM

    Dose-Dependent Effect of Metformin Preconditioning on the Regenerative Potential of Human Umbilical Cord-Derived Mesenchymal Stem Cells: An In Vitro Experimental Study

    Research SquarePreprint

  4. Metformin improves cell viability in human cells under Ang II challenge (89.7 ± 1.0% with 1.0 mM vs 53.0-64.9% with Ang II).

    “Metformin attenuated this injury in a concentration-dependent manner, restoring viability to 81.7 ± 1.0% with 0.5 mM and 89.7 ± 1.0% with 1.0 mM”

    Cellsunder Ang II challengeheart0.5 or 1.0 mM

    Metformin Attenuates Angiotensin II-Induced Cardiac Inflammaging-Like Injury Through Coordinated Nrf2 Activation and NF-κB Suppression

    Iranian journal of pharmaceutical research : IJPR

  5. Metformin decreases cell viability in human cells after 48 h (IC50 2.28 mM).

    “Metformin induced dose- and time-dependent cytotoxicity in all cell lines, with the lowest IC50 values in HeLa and A549 cells after 48 h (2.28 and 3.30 mM; p < 0.05).”

    Cellsafter 48 hcervical carcinoma cell line48 h

    Targeting Cancer Metabolism: Modulation of Metformin Antitumor Effects by Caffeine with Involvement of p53 Signaling

    Preprints.orgPreprint

  6. Metformin decreases cell viability in rat cells (at 100 mM) (complete loss).

    “a dose of 100 mM was cytotoxic to osteoblasts and resulted in a complete loss of their viability.”

    Cellsat 100 mM100 mM

    Dose-Dependent Impact of Metformin on Osteoblast-Specific Biomarkers in Cultured Rat Primary Osteoblasts

    Physiological research

  7. Metformin improves cell viability in rat cells (at concentrations up to 1 mM).

    “MET at concentrations up to 1 mM can promote osteoblast viability, osteogenic differentiation, angiogenic signaling, and reduce osteoclastogenesis.”

    Cellsat concentrations up to 1 mM

    Dose-Dependent Impact of Metformin on Osteoblast-Specific Biomarkers in Cultured Rat Primary Osteoblasts

    Physiological research

  8. Metformin increases cell viability in human cells (MPP+-treated cells; metformin pretreatment).

    “The results showed that pretreatment with metformin increased the viability of MPP+-treated SH-SY5Y cells.”

    CellsMPP+-treated cells; metformin pretreatmentdifferentiated SH-SY5Y cells

    Metformin restores the mitochondrial membrane potentials in association with a reduction in TIMM23 and NDUFS3 in MPP+-induced neurotoxicity in SH-SY5Y cells

    EXCLI journal

Apoptosis

upin human cells1downin mice1downin rat cells1downin rats1+1

5 studies
  1. Metformin decreases apoptosis in mice (benzalkonium chloride-induced dry eye disease).

    “In vivo, systemic administration of metformin preserved corneal epithelial thickness, decreased apoptosis, and reduced senescence markers in DED mice.”

    Animalsbenzalkonium chloride-induced dry eye diseasecorneal epithelium

    Metformin alleviates dry eye-associated corneal epithelial senescence and oxidative stress via AMPK activation

    Experimental eye research

  2. Metformin decreases apoptosis in rat cells (cells isolated from metformin-treated diabetic erectile dysfunction rats).

    “PCECs from DMBG-treated rats exhibited rescued viability, angiogenesis, migration, and reduced apoptosis, alongside reactivated autophagy.”

    Cellscells isolated from metformin-treated diabetic erectile dysfunction ratsprimary cavernosal endothelial cells

    Metformin (DMBG) ameliorates diabetic erectile dysfunction via the AMPK/mTOR pathway in association with endothelial autophagy reactivation

    Journal of reproductive immunology

  3. Metformin decreases apoptosis.

    “exhibiting several properties, including antioxidant, anti-inflammatory, and anti-apoptotic effects across various tissues”

    Reviewvarious tissues

    Mechanistic Insights into metformin's neuroprotective effects against drug-induced neurotoxicity

    Metabolic brain disease

  4. Metformin induces apoptosis in human cells.

    “Increased apoptosis and elevated p53 expression suggest activation of tumor-suppressive pathways.”

    Cellscervical carcinoma cell line

    Targeting Cancer Metabolism: Modulation of Metformin Antitumor Effects by Caffeine with Involvement of p53 Signaling

    Preprints.orgPreprint

  5. Metformin decreases apoptosis in SUI rats after double vaginal dilation.

    “TUNEL assay showed that metformin treatment reduced apoptotic cells in the EUS from SUI rats.”

    Animalsin SUI rats after double vaginal dilationexternal urethral sphincter200 mg/kg/day

    Metformin enhances external urethral sphincter integrity and restores continence via AMPK activation in a rat model of stress urinary incontinence

    Animal models and experimental medicine

More on Apoptosis

Vitamin B12

downin humans5

5 studies
  1. Metformin decreases vitamin B12 in humans.

    “Metformin assignment was associated with lower B12 levels over follow-up compared with placebo (β= -0.026, SE= 0.011, p= .0017).”

    Human trialover follow-up

    Long-Term Metformin Use and Vitamin B12 Deficiency in the Diabetes Prevention Program Outcomes Study (DPPOS)

    ADA Scientific Sessions 2026 abstract

  2. Metformin is linked with lower vitamin B12 in humans (mean 646.4 vs 707.4 pg/mL).

    “Metformin users also had lower vitamin B12 levels (mean, 646.4 vs 707.4 pg/mL)”

    Humans

    Metformin Use Is Associated With Reduced Rates of Primary Nerve Decompression Surgery and Revision in Type 2 Diabetes: A Retrospective Cohort Study

    Journal of hand surgery global online

  3. Metformin is linked with lower vitamin B12 in humans (type 2 diabetes) (569.3 vs. 825.3 pg/mL).

    “Metformin users had lower serum B12 (569.3 vs. 825.3 pg/mL; p = 0.026)”

    Humanstype 2 diabetesn = 587

    Metformin Use Is Associated With Better Cognitive Performance in Older Adults With Type 2 Diabetes: Exploratory Analysis of Vitamin B12 and Methylmalonic Acid Pathways in NHANES 2011-2014

    Diabetes, obesity & metabolism

  4. Metformin is linked with lower vitamin B12 in humans (T2DM patients on metformin therapy) (389.4 pg/mL (<1 year) to 196.8 pg/mL (>5 years) (p<0.001)).

    “Mean serum B12 declined significantly with increasing duration: 389.4 pg/mL (<1 year) to 196.8 pg/mL (>5 years) (p<0.001).”

    HumansT2DM patients on metformin therapyn = 312

    Retrospective Analysis Of Metformin Use And Its Association With Vitamin B12 Deficiency In Patients With Type 2 Diabetes Mellitus

    International Journal of Drug Delivery Technology

  5. Metformin is linked with lower vitamin B12 in type 2 diabetes mellitus (206.66 ± 59.09 pg/mL vs 301.44 ± 72.28 pg/mL).

    “The mean serum vitamin B12 level in metformin users was significantly lower than in controls (206.66 ± 59.09 pg/mL vs 301.44 ± 72.28 pg/mL, p < 0.001).”

    Humansin type 2 diabetes mellitus1238.89 ± 586.50 mg/day5.22 ± 3.77 years

    To Determine Vitamin B12 Deficiency in Type 2 Diabetes Mellitus Patients on Metformin Therapy

    The Journal of the Association of Physicians of India

More on Vitamin B12

Mortality

downin humans3upin humans1downin mice1OR 0.84

5 studies
  1. Metformin is linked with lower mortality in humans (aHR 0.75 (95% CI 0.73-0.77)).

    “Metformin users had lower observed all-cause mortality than DPP-4 inhibitor users (aHR, 0.75; 95% CI, 0.73-0.77)”

    Humansversus DPP-4 inhibitors, observed in a retrospective cohort with residual confounding possible

    Metformin versus DPP-4 inhibitors and risk of parkinsonism in type 2 diabetes: an active-comparator cohort study with a landmark design

    Diabetology & metabolic syndrome

  2. Metformin is linked with higher mortality in humans (glioblastoma) (HR = 1.22; 95% CI: 1.10-1.34).

    “linked to increased mortality between 3-9 months (HR = 1.22; 95% CI: 1.10-1.34)”

    Humansglioblastoma3-9 monthsn = 16,069

    Metformin exposure after glioblastoma diagnosis and mortality: A large population-based study

    Neuro-oncology advances

  3. Metformin decreases mortality in type 2 diabetes (OR 0.84, 0.74-0.95).

    “metformin lowered all-cause mortality risk by 16% (OR 0.84, 0.74-0.95)”

    Reviewin type 2 diabetesn = 939,064

    Antidiabetic drug and chronic respiratory disease in type 2 diabetes: a network meta-analysis and Mendelian randomization analysis

    Therapeutic advances in endocrinology and metabolism

  4. Metformin decreases mortality in diabetic and non-diabetic populations.

    “It has been shown that the anti-diabetic metformin reduces mortality and the incidence of several age-related diseases”

    Reviewin diabetic and non-diabetic populations

    Concept and connotation of the geroprotective and anti-aging effects of metformin: From AMPK activation to SASP suppression

    Molecular and cellular endocrinology

  5. Metformin decreases mortality in mice (pentylenetetrazol-induced seizures) (P < 0.001).

    “The mortality rate, the length of generalized tonic-clonic seizures, the frequency of seizures, and the seizure scores (P < 0.001) were all substantially reduced by the MET.”

    Animalspentylenetetrazol-induced seizures200, 250, and 300 mg/kg7 days

    Metformin ameliorates pentylenetetrazol-induced seizures in mice by modulating peroxisome proliferator-activated receptor gamma, nuclear factor-kappa B, matrix metalloproteinase 2, and caspase-3

    Journal of advanced pharmaceutical technology & research

Fasting blood glucose

downin humans2no changein rats1downin rats1

4 studies
  1. Metformin decreases fasting blood glucose in humans among women carrying a male foetus (mean glucose 4.88 mmol/L vs. 5.01 mmol/L).

    “Among women carrying a male foetus, metformin reduced the primary composite outcome (55% vs. 68%, p = 0.024), insulin use (38% vs. 53%, p = 0.014) and fasting glucose at 32 and 38 weeks (mean glucose 4.88 mmol/L vs. 5.01 mmol/L, p = 0.021 and 4.49 mmol/L vs. 4.69 mmol/L, p = 0.002), respectively.”

    Human trialamong women carrying a male foetusn = 289

    The role of male foetal sex on maternal and neonatal outcomes in pregnancies complicated by gestational diabetes-secondary analysis of a randomised placebo controlled clinical trial of metformin in gestational diabetes (EMERGE)

    BMC medicine

  2. Metformin decreases fasting blood glucose in male pregnancies complicated by GDM (4.88 vs. 5.01 mmol/L, p = 0.014 at 32 weeks; 4.49 vs. 4.69 mmol/L, p = 0.002 at 38 weeks).

    “metformin exposure in male pregnancies was associated with lower fasting glucose at 32 (4.88 vs. 5.01 mmol/L, p = 0.014) and 38 weeks (4.49 vs. 4.69 mmol/L, p = 0.002)”

    Human trialin male pregnancies complicated by GDMmales

    The role of male foetal sex on maternal and neonatal outcomes in pregnancies complicated by gestational diabetes-secondary analysis of a randomised placebo controlled clinical trial of metformin in gestational diabetes (EMERGE)

    BMC medicine

  3. Metformin showed no clear effect on fasting blood glucose in rats (streptozotocin-induced diabetes; evaluated at week 8).

    “final fasting blood glucose did not differ significantly between T and D4.”

    Animalsstreptozotocin-induced diabetes; evaluated at week 8100 mg/kg/daymales

    Effects of Metformin Treatment on Liver Glucose Metabolism-Related Enzyme Levels in Streptozotocin-Induced Diabetic Rats

    Journal of clinical medicine

  4. Metformin decreases fasting blood glucose in humans (pregnant women with gestational diabetes mellitus; compared with insulin) (SMD -0.29 (95% CI -0.55 to -0.03)).

    “Metformin achieved glycemic control comparable to insulin, with a pooled SMD for fasting blood glucose (FBG) of -0.29 (95% CI: -0.55 to -0.03; P = 0.03).”

    Reviewpregnant women with gestational diabetes mellitus; compared with insulinfemales

    Treatment outcomes and safety of metformin versus insulin in gestational diabetes mellitus: A systematic review and meta-analysis

    Journal of family medicine and primary care

  5. Metformin decreases fasting blood glucose in high-fat diet and STZ-induced T2DM rats.

    “Metformin produced the greatest reductions in FBG, cholesterol, creatinine, and glycated hemoglobin.”

    Animalsin high-fat diet and STZ-induced T2DM rats28 daysmalesn = 30

    Antidiabetic effects of Gymnema sylvestre and metformin co-therapy in a type 2 diabetic rat model

    World journal of experimental medicine

More on Fasting blood glucose

HbA1c

downin humans4

4 studies
  1. Metformin decreases HbA1c in humans (Prediabetes and body mass index ≥23 kg/m2).

    “a significant reduction in HbA1c was observed only in the MET group.”

    Human trialPrediabetes and body mass index ≥23 kg/m26 monthsn = 217

    Effects of a 6-Month Intervention on Body Weight and Cardiometabolic Parameters Based on the Korean Diabetes Prevention Study

    Diabetes & metabolism journal

  2. Metformin is linked with lower HbA1c in humans (Newly diagnosed type 2 diabetes mellitus; no prior oral hypoglycemic medication) (6.85% versus 7.29% at baseline).

    “The HbA1c level significantly reduced after the 12-week treatment period (6.85% vs 7.29% at baseline, P = .001).”

    HumansNewly diagnosed type 2 diabetes mellitus; no prior oral hypoglycemic medication12 weeksn = 68

    Effectiveness of metformin as initial treatment on the metabolic profile of Saudi patients newly diagnosed with type 2 diabetes mellitus: A prospective observational study

    Medicine

  3. Metformin is linked with lower HbA1c in humans (newly diagnosed type 2 diabetes) (median 7.8 to 7.2; p = 0.001).

    “The HbA1c level decreased from 7.8 (6.9-8.9) to 7.2 (6.5-8.1) (p = 0.001).”

    Humansnewly diagnosed type 2 diabetessix monthsn = 52

    Assessing Cognitive Responses and Serum Vitamin B₁₂ Levels in Newly Diagnosed Type 2 Diabetes Mellitus Patients Treated With Metformin: A Prospective Study

    Cureus

  4. Metformin decreases HbA1c in humans (MD -0.070%).

    “At 12 months, metformin significantly reduced waist circumference (MD -1.12 cm; p = 0.014), HbA1c (MD -0.070%; p = 0.029)”

    ReviewAdded to androgen-deprivation therapy in prostate cancer, versus androgen-deprivation therapy alone12 months

    Metabolic and oncological effects of metformin added to ADT in prostate cancer: systematic review and meta-analysis including STAMPEDE

    Prostate cancer and prostatic diseases

More on HbA1c

IL-6

downin humans2downin human cells1

3 studies
  1. Metformin decreases IL-6 in humans (Peri-implantitis; adjunctive to mechanical debridement versus mechanical debridement alone) (8.13 pg/mL vs. 19.23 pg/mL).

    “IL-6 levels (8.13 pg/mL vs. 19.23 pg/mL, P < 0.001) compared with the control.”

    Human trialPeri-implantitis; adjunctive to mechanical debridement versus mechanical debridement alonegelperi-implant crevicular fluid1%6 monthsn = 54

    Harnessing the Therapeutic Potential of Locally Delivered 1% Metformin Gel for Modulation of Clinical and Inflammatory Parameters in Peri-Implantitis Disease: A Prospective Clinical Evaluation

    Journal of long-term effects of medical implants

  2. Metformin is linked with lower IL-6 in humans (patients with newly diagnosed T2DM).

    “significant reductions in TNF-α, IL-6, glycated hemoglobin (HbA1c), and fasting plasma glucose levels were observed in both groups (p < 0.001)”

    Humanspatients with newly diagnosed T2DM6 months

    Effects of Metformin Monotherapy Versus Metformin Plus SGLT-2 Inhibitor Therapy on Molecular and Cellular Inflammatory Markers in Patients with Newly Diagnosed Type 2 Diabetes Mellitus

    Journal of clinical medicine

  3. Metformin decreases IL-6 in PDGFβ-treated orbital fibroblasts from TED patients.

    “Metformin treatment restored AMPK phosphorylation, reduced HA accumulation (∼2.3-3.1-fold), and decreased IL-6 and IL-8 production.”

    Cellsin PDGFβ-treated orbital fibroblasts from TED patients

    Metformin inhibits PDGFβ signaling to suppress hyaluronan and cytokine production in thyroid eye disease

    Experimental eye research

More on IL-6

HOMA-IR

upin humans1no changein humans1downin humans1

3 studies
  1. Metformin improves HOMA-IR in patients of schizophrenia with metabolic syndrome.

    “Metformin showed significant within-group improvements in LDL: HDL ratio and HOMA-IR”

    Human trialin patients of schizophrenia with metabolic syndrome1000 mg/dayeight weeks

    Efficacy and safety of add-on topiramate vs. metformin on cardiometabolic profile in patients of schizophrenia on atypical antipsychotics with metabolic syndrome: an active-controlled, rater-blinded, parallel-design randomized controlled trial

    European archives of psychiatry and clinical neuroscience

  2. Metformin showed no clear effect on HOMA-IR in 21OHD patients (median HOMA-IR, 2.50-2.82).

    “Daily 1000 mg metformin therapy for 6 months did not significantly improve IR (median HOMA-IR, 2.50-2.82; p = 0.460)”

    Human trialin 21OHD patients1000 mg daily6 months

    Insulin Resistance Emerges Early After Glucocorticoid Treatment in Adult Patients With 21-Hydroxylase Deficiency

    Journal of diabetes

  3. Metformin decreases HOMA-IR in humans.

    “Over the 12-week period, significant time effects were observed for glucose, HOMA-IR, and RBP4 (p < 0.05), as well as for total cholesterol levels (p < 0.01).”

    Human trialtwelve-weekfemalesn = 30

    Multi-strain probiotic reduces gastrointestinal side effects in women with elevated HOMA-IR index treated with metformin: a 12-week randomised controlled trial

    Frontiers in endocrinology

More on HOMA-IR

Frailty

downin humans1no changein humans1downin mice1

3 studies
  1. Metformin decreases frailty in humans (frailty index progression, adjusted for covariates including body mass index) (-0.006±0.0026 per year vs. placebo).

    “Notably, metformin caused a steady improvement in the frailty index (-0.006±0.0026 per year vs. placebo, p=0.0222)”

    Human trialfrailty index progression, adjusted for covariates including body mass indextwo yearsn = 145

    A Randomized Clinical Trial of Metformin to Reduce Frailty in Older Adults with Glucose Intolerance

    medRxiv : the preprint server for health sciencesPreprint

  2. Metformin showed no clear effect on frailty in non-diabetic people living with HIV (94.1% to 58.8% vs. 88.9% to 77.8%).

    “According to the Fried phenotype, the proportion of robust individuals decreased from 94.1% at baseline to 58.8% at week 96 in the metformin group, and from 88.9% to 77.8% in the placebo group, but these changes were not statistically significant (p = 0.355).”

    Human trialin non-diabetic people living with HIV96 weeksn = 35

    Metformin and epigenetic age in non-diabetic older people with HIV in Madrid (METFORAGING): a double-blind, randomised, placebo-controlled, pilot trial

    EClinicalMedicine

  3. Metformin decreases frailty in mice.

    “Both clinical and performance-based frailty scores were significantly attenuated.”

    Animals30 to 53 weeks of agemales

    Metformin promotes healthspan by attenuating frailty and preserving musculoskeletal function-structure in middle-aged mice

    Biogerontology

All 443

What is metformin linked with?

124

Studies link metformin with 124 measures, most often mortality (10 studies), vitamin B12 deficiency (6) and dementia (5).

Mortality

downin humans9no changein humans1HR 0.19–0.83

10 studies
  1. Metformin is associated with mortality in humans (HR 0.60, 95% CI 0.55-0.66).

    “All active therapies were associated with lower mortality compared with no observed therapy, including GLP-1RA/SGLT2i (HR 0.71, 95% CI 0.58-0.87), metformin (HR 0.60, 95% CI 0.55-0.66)”

    HumansType 2 diabetes after isolated coronary artery bypass grafting; compared with no observed therapyn = 19,237

    Initial Diabetes Therapy After Coronary Artery Bypass Grafting and Long-Term Outcomes

    Journal of the American Heart Association

  2. Metformin is associated with mortality in humans (Type 2 diabetes and COVID-19; compared with DPP4 inhibitor prescription) (aRR 0.61, 95% CI 0.51–0.73).

    “metformin prescription was associated with a lower risk of all‐cause mortality after COVID‐19 (adjusted risk ratio [aRR]: 0.61, 95% CI: 0.51, 0.73).”

    HumansType 2 diabetes and COVID-19; compared with DPP4 inhibitor prescription12 monthsn = 53,332

    Metformin linked to lower death risk after COVID-19 in diabetes

    Diabetes, obesity & metabolism

  3. Metformin is associated with mortality in humans (Cancer patients initiating vascular endothelial growth factor inhibitor therapy) (19.8% vs. 23.0%; HR 0.83, 95% CI 0.79-0.87).

    “metformin use was associated with a marked reduction in all-cause mortality and new-onset metastatic disease.”

    HumansCancer patients initiating vascular endothelial growth factor inhibitor therapyUp to one year

    Metformin for Cardioprotection During Vascular Endothelial Growth Factor Inhibitor Therapy: A Retrospective Cohort Study

    AHA Scientific Sessions 2026 abstract

  4. Metformin is associated with mortality in humans (Cardiometabolic HFpEF) (HR 0.19, 95% CI 0.05–0.78).

    “Statin use (HR = 0.55, 95% CI 0.35-0.86) and metformin (HR = 0.19, 95% CI 0.05-0.78) showed significant protective effects overall.”

    HumansCardiometabolic HFpEFn = 1,158

    Prognosis and treatment response in cardiometabolic HFpEF: deep learning-based phenomapping with a pragmatic clinical classifier

    ESC Congress 2026 abstract

  5. Metformin is associated with mortality in humans (type II diabetes).

    “Hazard ratios of all-cause mortality were lower among Metformin (HR=0.61, CI=0.31-1.16) and Metformin Combo group (HR=0.96, CI=0.61-1.52) compared to Sulfonylureas (though statistically not significant).”

    Humanstype II diabetesn = 120

    Does Metformin intake reduce the risk of all-cause mortality among diabetic Mexican Americans living along the Texas-Mexico border in the US

    Preprint

  6. Metformin is linked with a lower risk of mortality in the long-term period after COVID-19 in patients with T2DM (HR 0.40; 95% CI 0.30–0.54, p<0.001).

    “A lower risk of death in the long-term period was associated with the use of SGLT2 inhibitors (HR 0.45; 95% CI 0.29–0.70, p<0.001) and metformin (HR 0.40; 95% CI 0.30–0.54, p<0.001).”

    Humansin the long-term period after COVID-19 in patients with T2DM

    Mortality in patients with type 2 diabetes mellitus following coronavirus infection during the acute phase and long-term period

    Diabetes Mellitus

  7. Metformin is linked with a lower risk of mortality in humans (HR 0.828, 95% CI 0.799-0.857).

    “metformin and thiazolidinedione (TZD) exposure were associated with lower mortality (HR 0.828, 95% CI 0.799-0.857 and HR 0.838, 95% CI 0.793-0.885, respectively)”

    Humansafter adjustment for demographics, comorbid conditions, renal function, and hemoglobin A1c; veterans with pulmonary hypertension and diabetes

    Association of Antidiabetic Medication Classes With Survival Outcomes in Pulmonary Hypertension Patients With Diabetes

    Pulmonary circulation

  8. Metformin is linked with a lower risk of mortality in humans (patients with type 2 diabetes mellitus without known heart failure) (HR: 0.410, p = 0.019).

    “Metformin use was independently associated with lower mortality risk (HR: 0.410, p = 0.019).”

    Humanspatients with type 2 diabetes mellitus without known heart failuremedian follow-up of 61 monthsn = 449

    The WATCH-DM integer-based risk score identifies risk of all-cause mortality in patients with type 2 diabetes: a retrospective cohort study

    Therapeutic advances in endocrinology and metabolism

  9. Metformin is associated with mortality in humans (pooled across mixed human studies in patients with cancer) (HR=0.82, 95% CI: 0.74-0.91).

    “Metformin use was associated with lower ACM (HR=0.82, 95% CI: 0.74-0.91, P=0.0001)”

    Reviewpooled across mixed human studies in patients with cancer

    Heterogeneous associations of antidiabetic medications with cancer prognosis: Evidence from 61 studies with over 1.1 million patients

    Pharmacological research

  10. Metformin lowers the risk of mortality in people with type 2 diabetes.

    “Metformin use in individuals with T2DM was associated with reduced risk of all-cause mortality, incidence of CVDs, and dementia.”

    Reviewin people with type 2 diabetes

    Impact of Metformin on Healthspan-Related Outcomes and Incidence of Diseases of Aging in People with Type 2 Diabetes Mellitus: A Systematic Review

    Rejuvenation research

Vitamin B12 deficiency

upin humans6OR 1.49–5.33

6 studies
  1. Metformin raises the risk of vitamin B12 deficiency in humans (OR 1.49, 95% CI 1.08-1.91).

    “participants in the metformin arm had higher odds of B12 deficiency than those receiving placebo (OR= 1.49, 95% CI: 1.08-1.91, p= 0.004).”

    Human trialover follow-up

    Long-Term Metformin Use and Vitamin B12 Deficiency in the Diabetes Prevention Program Outcomes Study (DPPOS)

    ADA Scientific Sessions 2026 abstract

  2. Metformin is linked with a higher risk of vitamin B12 deficiency in humans (T2DM patients on metformin therapy) (OR 2.34; 95% CI 1.45-3.78).

    “Higher daily doses (>1500 mg/day) were independently associated with deficiency (OR 2.34; 95% CI 1.45-3.78).”

    HumansT2DM patients on metformin therapy>1500 mg/dayn = 312

    Retrospective Analysis Of Metformin Use And Its Association With Vitamin B12 Deficiency In Patients With Type 2 Diabetes Mellitus

    International Journal of Drug Delivery Technology

  3. Metformin is linked with a higher risk of vitamin B12 deficiency in adults with type 2 diabetes mellitus (adjusted OR: 2.85; 95% CI: 1.32-6.12).

    “multivariate logistic regression analysis identified metformin use for more than five years (adjusted odds ratio (OR): 2.85; 95% confidence interval (CI): 1.32-6.12)”

    Humansin adults with type 2 diabetes mellitusmore than five yearsn = 170

    Prevalence of Vitamin B12 Deficiency Among Patients With Type 2 Diabetes Mellitus on Long-Term Metformin Therapy

    Cureus

  4. Metformin is linked with a higher risk of vitamin B12 deficiency in type 2 diabetes mellitus (OR 5.33, 95% CI 2.44-11.65).

    “Vitamin B12 deficiency was present in 40.0% of metformin users versus 11.1% of controls, yielding an odds ratio of 5.33 (95% CI: 2.44-11.65)”

    Humansin type 2 diabetes mellitus1238.89 ± 586.50 mg/day5.22 ± 3.77 years

    To Determine Vitamin B12 Deficiency in Type 2 Diabetes Mellitus Patients on Metformin Therapy

    The Journal of the Association of Physicians of India

  5. Metformin is associated with vitamin B12 deficiency in humans (Higher metformin dose in patients with type 2 diabetes mellitus) (Dose AOR 1.002; 95% CI 1.001–1.003).

    “metformin dose (AOR: 1.002; 95% CI: 1.001 to 1.003; p < 0.001)”

    HumansHigher metformin dose in patients with type 2 diabetes mellitusn = 318

    Prevalence and Risk Factors of Vitamin B12 Deficiency in Type 2 Diabetes Mellitus Patients on Metformin at a Tertiary Care Center of Nepal

    Kathmandu University medical journal (KUMJ)

  6. Metformin is associated with vitamin B12 deficiency in humans (Adults with type 2 diabetes mellitus in Africa).

    “Narrative synthesis suggested that older age, longer metformin exposure, and higher metformin doses were the most consistently reported factors associated with vitamin B12 deficiency.”

    ReviewAdults with type 2 diabetes mellitus in Africahigher metformin doseslonger metformin exposure

    Vitamin B12 Deficiency in Metformin-Treated Adults with Type 2 Diabetes Mellitus in Africa: A Systematic Review and Meta-analysis

    Metabolism open

More on Vitamin B12 deficiency

Dementia

downin humans5HR 0.9

5 studies
  1. Metformin lowers the risk of dementia in humans (compared with placebo) (OR 0.40, 95% CI 0.17–0.97).

    “randomization to metformin was associated with a 60% (OR 0.40 [95% confidence interval 0.17, 0.97]) and 62% (OR 0.38 [95% confidence interval 0.16, 0.89]) lower odds of dementia compared with placebo and ILS, respectively”

    Human trialcompared with placeboaverage intervention duration of 3.2 yearsn = 1,483

    Randomized metformin and cognitive outcomes in the Diabetes Prevention Program Outcomes Study

    medRxiv : the preprint server for health sciencesPreprint

  2. Metformin lowers the risk of dementia in humans (compared with placebo) (60% lower odds (OR 0.40 [95%CI 0.17, 0.97])).

    “randomization to metformin was associated with a 60% (OR 0.40 [95%CI 0.17, 0.97]) and 62% (OR 0.38 [95%CI 0.16, 0.89]) lower odds of dementia compared with placebo”

    Human trialcompared with placebo

    Randomized metformin and cognitive outcomes in the Diabetes Prevention Program Outcomes Study

    medRxiv : the preprint server for health sciencesPreprint

  3. Metformin is associated with dementia in humans (59-62% lower odds vs placebo; 60% lower odds vs intensive lifestyle).

    “Randomization to MET was associated with 59-62% and 60% lower odds of dementia compared with PBO and ILS, respectively”

    Human trialrandomized allocation to metformin vs placebo or intensive lifestyle, prevalent cognitive impairment assessed 2022-2024n = 1,483

    Association of Randomization to Metformin with Prevalent Cognitive Impairment Syndromes in the Diabetes Prevention Program Outcomes Study

    ADA Scientific Sessions 2026 abstract

  4. Metformin is associated with dementia in humans (Metformin initiation compared with sulfonylurea initiation) (HR 0.90, 95% CI 0.82–1.02).

    “a lower incidence of dementia (HR: 0.90, 95% CI: [0.82, 1.02]).”

    HumansMetformin initiation compared with sulfonylurea initiation

    Metformin linked to lower dementia risk in US health records

    medRxivPreprint

  5. Metformin is linked with a lower risk of dementia in humans (compared with placebo, Bayesian network meta-analysis) (OR 0.79, 95% CrI 0.77–0.81).

    “Metformin [OR = 0.79, 95% CrI (0.77, 0.81)]”

    Humanscompared with placebo, Bayesian network meta-analysis

    The impact of antidiabetic drugs on dementia risk: a Bayesian network meta-analysis

    Frontiers in endocrinology

  6. Metformin lowers the risk of dementia in people with type 2 diabetes.

    “Metformin use in individuals with T2DM was associated with reduced risk of all-cause mortality, incidence of CVDs, and dementia.”

    Reviewin people with type 2 diabetes

    Impact of Metformin on Healthspan-Related Outcomes and Incidence of Diseases of Aging in People with Type 2 Diabetes Mellitus: A Systematic Review

    Rejuvenation research

More on Dementia

Type 2 diabetes

downin humans3RR 0.65

3 studies
  1. Metformin lowers the risk of type 2 diabetes in humans (RR = 0.65, 95% CI [0.55, 0.77]).

    “The meta-analysis showed that metformin use was associated with a significantly lower risk of progression to T2DM compared with the non-metformin control group (RR = 0.65, 95% CI [0.55, 0.77], P < 0.00001), corresponding to a 35% risk reduction.”

    Human trial

    Meta-Analysis of the Effect of Metformin on the Progression of Different Types of Prediabetes Mellitus

    Diabetes, metabolic syndrome and obesity : targets and therapy

  2. Metformin lowers the risk of type 2 diabetes in humans (prediabetes) (RR 0.65, 95% CI 0.55–0.77).

    “Metformin reduced the risk of progression to T2DM by 35% compared with lifestyle intervention or placebo (RR = 0.65; 95% CI: 0.55-0.77; P < 0.00001)”

    Human trialprediabetes

    Meta-Analysis of the Effect of Metformin on the Progression of Different Types of Prediabetes Mellitus

    Diabetes, metabolic syndrome and obesity : targets and therapy

  3. Metformin lowers the risk of type 2 diabetes in humans (HR 0.58 (95% CI 0.24–1.32)).

    “The hazard ratio for new onset T2DM comparing metformin to placebo was 0.58 (95% CI: 0.24 - 1.32) in the primary analytic model”

    Human trialprimary Cox model adjusted for baseline vaccination status and other study drugs; 10 months after randomizationimmediate-release metformin hydrochloride10 monthsn = 1,136

    Can 14 Days of Metformin Prevent Post-COVID Diabetes?

    ADA Scientific Sessions 2026 abstract

  4. Metformin lowers the risk of type 2 diabetes in selected high-risk individuals with prediabetes.

    “Metformin remains the glucose-lowering agent with the most established long-term evidence for diabetes prevention in selected high-risk individuals with prediabetes”

    Reviewin selected high-risk individuals with prediabetes

    From insulin resistance to incretin receptor agonism in the prevention of type 2 diabetes mellitus in obese individuals

    Current medical research and opinion

More on Type 2 diabetes

Glaucoma

no changein humans2downin humans2OR 0.96

3 studies
  1. Metformin is associated with glaucoma in humans (newly diagnosed type 2 diabetes mellitus) (adjusted HR 1.076, 95% CI 0.995-1.163, p=0.067).

    “metformin monotherapy (N=100,387) showed a non-significant trend toward higher glaucoma diagnosis rates compared to matched controls (HR 1.106, 95% CI 1.014-1.207, p=0.023; adjusted HR 1.076, 95% CI 0.995-1.163, p=0.067).”

    Humansnewly diagnosed type 2 diabetes mellitusn = 100,387

    Glaucoma Risk with Metformin and Sulfonylurea Therapies in Type 2 Diabetes: A Retrospective Cohort Study

    Clinical ophthalmology (Auckland, N.Z.)

  2. Metformin is linked with a lower risk of glaucoma in humans (individuals of European ancestry with diabetes) (HR 0.81, 95% CI 0.67-0.97).

    “Metformin use was associated with a 19% lower glaucoma risk (hazard ratio, 0.81; 95% confidence interval [CI], 0.67-0.97; P = 0.019) in individuals of European ancestry”

    Humansindividuals of European ancestry with diabetes12.1 ± 2.8 yearsn = 24,206

    Protective Role of Metformin in Glaucoma: Prospective Cohort Study, Meta-Analysis, and Drug-Target Mendelian Randomization

    Ophthalmology science

  3. Metformin lowers the risk of glaucoma in humans (time-to-event analysis, adjusted models) (aHR = 0.88; 95% CI, 0.80-0.96).

    “persisted in adjusted models (aHR = 0.88; 95% CI, 0.80-0.96; I2 = 0.01%; moderate certainty).”

    Reviewtime-to-event analysis, adjusted models

    Metformin Use and Risk of Glaucoma: A Systematic Review and Meta-Analysis

    American journal of ophthalmology

  4. Metformin is associated with glaucoma in humans (crude binary analysis) (OR = 0.96; 95% CI, 0.87-1.06).

    “The pooled crude OR showed no association between metformin use and glaucoma risk (OR = 0.96; 95% CI, 0.87-1.06; I2 = 79.14%; low certainty).”

    Reviewcrude binary analysis

    Metformin Use and Risk of Glaucoma: A Systematic Review and Meta-Analysis

    American journal of ophthalmology

More on Glaucoma

Cognitive function

upin humans3

3 studies
  1. Metformin is associated with cognitive function in humans (Community-dwelling older adults with type 2 diabetes; metformin users versus non-users) (MMSE change 0.0 versus −0.7; p<0.001; unlikely to be clinically meaningful in the short term).

    “At 2 years, metformin users maintained stable MMSE scores, while non-users showed a slight decrease (0.0 vs −0.7; p<0.001)”

    HumansCommunity-dwelling older adults with type 2 diabetes; metformin users versus non-users2 years46.1% womensn = 412

    Is metformin use associated with cognitive, physical and cardiovascular outcomes in older adults with type 2 diabetes? A secondary analysis of the SCOPE multicentre prospective cohort study

    BMJ open

  2. Metformin is associated with cognitive function in humans (type 2 diabetes) (47.5 vs. 39.5).

    “Metformin is associated with better cognition in older T2DM adults.”

    Humanstype 2 diabetesn = 587

    Metformin Use Is Associated With Better Cognitive Performance in Older Adults With Type 2 Diabetes: Exploratory Analysis of Vitamin B12 and Methylmalonic Acid Pathways in NHANES 2011-2014

    Diabetes, obesity & metabolism

  3. Metformin is associated with cognitive function in humans.

    “Metformin-treated patients had higher Mini-ACE scores and elevated serum BDNF and NGF.”

    Humans

    Neuropsychiatric and neurocognitive outcomes of metformin versus insulin therapy in Egyptian patients with type 2 diabetes: focus on NGF and BDNF; a cross-sectional study

    The Egyptian Journal of Internal Medicine

Survival

upin humans1upin zebrafish1

2 studies
  1. Metformin is associated with survival in zebrafish (co-administered with high glucose (150 mM)).

    “Metformin was associated with improved survival, cardiac phenotypes, and locomotor outcomes, together with partial molecular restoration.”

    Animalsco-administered with high glucose (150 mM)0.75, 3.0, or 6.0 mM

    Metformin Attenuates Cardiac Developmental Toxicity in High-Glucose-Exposed Zebrafish Larvae: Oxidative Stress, Hif-1α-Associated Metabolic Gene Alterations, and Wnt Signaling Changes

    Pharmaceuticals (Basel, Switzerland)

  2. Metformin is associated with survival in humans (selected patients with cirrhosis).

    “metformin use is associated with improved survival in selected patients with cirrhosis”

    Reviewselected patients with cirrhosis

    Metformin for the treatment of chronic liver disease: Mechanistic rationale, translational evidence, and repurposing opportunities

    Biochemical pharmacology

Gut microbial composition

mixedin mice1mixedin reviews1

2 studies
  1. Metformin is associated with gut microbial composition.

    “Metformin is consistently associated with reshaping of gut microbial composition, enriching Akkermansia muciniphila and short-chain fatty acid (SCFA)- producing taxa”

    Reviewgut

    Gut Microbiota and Antidiabetic Drugs: A bidirectional relationship

    Frontiers in pharmacology

  2. Metformin is associated with gut microbial composition in mice (LPS-induced injury).

    “Metagenomics showed metformin-associated remodeling of gut microbial composition and predicted gene-content functional potential.”

    AnimalsLPS-induced injurycolonic contents400 mg/kg7 days before intranasal LPS challengemales

    Multi-Omics Analysis Identifies Gut-Associated Metabolic Signatures Associated with Metformin-Mediated Protection Against LPS-Induced Lung Injury

    Pharmaceuticals (Basel, Switzerland)

More on Gut microbial composition

Cardiovascular disease

downin humans2OR 0.69

2 studies
  1. Metformin lowers the risk of cardiovascular disease in humans (versus placebo in type 2 diabetes) (OR 0.69, 95% CI 0.53-0.89).

    “metformin (OR 0.69, 95% CI 0.53-0.89), SGLT2i (0.82, 0.75-0.90), GLP1RA (0.87, 0.83-0.92) and tirzepatide (0.82, 0.72-0.93) were associated with a significant reduction of MACE versus placebo”

    Human trialversus placebo in type 2 diabetesat least 40 weeks

    Effect of Medications for Type 2 Diabetes on Cardiovascular Events and Mortality: A Comprehensive Pairwise and Network Meta-Analysis

    Diabetes, obesity & metabolism

  2. Metformin lowers the risk of cardiovascular disease in people with type 2 diabetes.

    “Metformin use in individuals with T2DM was associated with reduced risk of all-cause mortality, incidence of CVDs, and dementia.”

    Reviewin people with type 2 diabetes

    Impact of Metformin on Healthspan-Related Outcomes and Incidence of Diseases of Aging in People with Type 2 Diabetes Mellitus: A Systematic Review

    Rejuvenation research

More on Cardiovascular disease

Lactic acidosis

upin humans2HR 3.14

2 studies
  1. Metformin is linked with a higher risk of lactic acidosis in very elderly patients with CKD and type 2 diabetes (HR 3.14 (95% CI 1.75-5.65)).

    “and lactic acidosis (HR 3.14; 95% CI 1.75-5.65)”

    Humansin very elderly patients with CKD and type 2 diabetes

    Metformin Use and Clinical Outcomes in Very Elderly Patients with Type 2 Diabetes and Chronic Kidney Disease

    Medicina (Kaunas, Lithuania)

  2. Metformin raises the risk of lactic acidosis in humans (renal-impaired or elderly patients).

    “contrasted by long-term risks like lactic acidosis and neurodegeneration in renal-impaired or elderly patients.”

    Reviewrenal-impaired or elderly patientslong-term

    Metformin's disruption of gluconeogenesis in type 2 diabetes impairments of the cori and alanine cycles as hidden drivers of metabolic waste accumulation, NF-κBHIF-1α-mediated low-grade inflammation, and multisystem dysfunction

    Problemy endokrinologii

More on Lactic acidosis

Low birth weight

upin humans1

1 study
  1. Metformin raises the risk of low birth weight in humans among women carrying a female foetus (8.3% vs. 1.9%).

    “Among women carrying a female foetus, metformin usage was associated with reduced maternal weight gain (0.5 vs. 2.3 kg, p < 0.001), lowered fasting glucose at 38 weeks (4.47 mmol/L vs. 4.63 mmol/L, p = 0.046) and a higher rate of low birth weight infants (8.3% vs. 1.9%, p = 0.032) compared to placebo use”

    Human trialamong women carrying a female foetusn = 236

    The role of male foetal sex on maternal and neonatal outcomes in pregnancies complicated by gestational diabetes-secondary analysis of a randomised placebo controlled clinical trial of metformin in gestational diabetes (EMERGE)

    BMC medicine

  2. Metformin raises the risk of low birth weight in female pregnancies complicated by GDM (8.3% vs. 1.9%, p = 0.032).

    “Metformin-exposed females had higher rates of birth weight < 2500 g compared to those exposed to placebo (8.3% vs. 1.9%, p = 0.032)”

    Human trialin female pregnancies complicated by GDMfemales

    The role of male foetal sex on maternal and neonatal outcomes in pregnancies complicated by gestational diabetes-secondary analysis of a randomised placebo controlled clinical trial of metformin in gestational diabetes (EMERGE)

    BMC medicine

Testosterone

downin humans1

1 study
  1. Metformin is associated with testosterone in humans (PCOS; before-and-after comparison without an untreated comparator) (0.81 ± 0.07 to 0.73 ± 0.08 ng/mL).

    “Testosterone declined significantly from 0.81 ± 0.07 to 0.73 ± 0.08 ng/mL (p < 0.001)”

    Human trialPCOS; before-and-after comparison without an untreated comparatormaximum of 2.55–3.0 g/day6 monthsfemalesn = 120

    Impact of Metformin on Gonadotropic Hormones, Prolactin Fractions, and Androgen Profile in Women with Polycystic Ovary Syndrome and Prediabetes: A Prospective Comparative Study

    Pathophysiology : the official journal of the International Society for Pathophysiology

More on Testosterone

Luteinizing hormone

downin humans1

1 study
  1. Metformin is associated with luteinizing hormone in humans (PCOS; before-and-after comparison without an untreated comparator) (11.28 ± 1.34 to 8.55 ± 1.11 IU/L).

    “In women with PCOS, LH decreased significantly from 11.28 ± 1.34 to 8.55 ± 1.11 IU/L (p < 0.001)”

    Human trialPCOS; before-and-after comparison without an untreated comparatormaximum of 2.55–3.0 g/day6 monthsfemalesn = 120

    Impact of Metformin on Gonadotropic Hormones, Prolactin Fractions, and Androgen Profile in Women with Polycystic Ovary Syndrome and Prediabetes: A Prospective Comparative Study

    Pathophysiology : the official journal of the International Society for Pathophysiology

More on Luteinizing hormone

Total prolactin

downin humans1

1 study
  1. Metformin is associated with total prolactin in humans (Prediabetes without PCOS; before-and-after comparison without an untreated comparator) (45.51 ± 5.05 to 37.87 ± 4.63 ng/mL).

    “whereas they decreased significantly in controls (45.51 ± 5.05 to 37.87 ± 4.63 ng/mL; p < 0.001)”

    Human trialPrediabetes without PCOS; before-and-after comparison without an untreated comparatormaximum of 2.55–3.0 g/day6 monthsfemalesn = 120

    Impact of Metformin on Gonadotropic Hormones, Prolactin Fractions, and Androgen Profile in Women with Polycystic Ovary Syndrome and Prediabetes: A Prospective Comparative Study

    Pathophysiology : the official journal of the International Society for Pathophysiology

More on Total prolactin

HOMA1-IR

downin humans1

1 study
  1. Metformin is associated with HOMA1-IR in humans (PCOS; before-and-after comparison without an untreated comparator) (3.27 ± 0.36 to 2.83 ± 0.39).

    “The Homeostatic Model Assessment for Insulin Resistance (HOMA1-IR) also decreased significantly, from 3.27 ± 0.36 to 2.83 ± 0.39 (p < 0.001)”

    Human trialPCOS; before-and-after comparison without an untreated comparatormaximum of 2.55–3.0 g/day6 monthsfemalesn = 120

    Impact of Metformin on Gonadotropic Hormones, Prolactin Fractions, and Androgen Profile in Women with Polycystic Ovary Syndrome and Prediabetes: A Prospective Comparative Study

    Pathophysiology : the official journal of the International Society for Pathophysiology

More on HOMA1-IR

All 124

Has metformin been tested in people?

140 of 1,170 about aging

Yes: 220 trials and 503 observational studies in people have been published, and 1,152 trials are registered.

Latest change Prediabetes: Human trials → Phase 3Nov 16, 2026

Approved

Repurposing

40 of 300

Every condition in trials

  • Prostatic neoplasm

    Phase 4Status unknown22 trials

  • Motor Activity

    Phase 4Results posted8 trials

  • Lipoatrophic diabetes mellitus

    Phase 4Completed6 trials

  • Fasting

    Phase 4Completed3 trials

  • Melanosis

    Phase 4Status unknown2 trials

  • Other Conditions That May Be A Focus of Clinical Attention

    Phase 4Results posted2 trials

40 of 74

Stopped

  • NCT02409238TerminatedType 2 diabetes

    1. Limits of grant funding reached 2. A/Prof Ng Tze Pin (P.I. \& holder of NMRC Grant (CIRG12may033) funding this study) retired in Aug 2022. 3. Resignations of staff and collaborators especially over the 1st 2 years of the COVID-19 pandemic

  • NCT03118713TerminatedType 2 diabetes

    Business decision due to enrollment challenges

  • NCT03258723TerminatedDiabetes mellitus

    COVID-19 led to changes in study design and an early end to data collection.

  • NCT04416269TerminatedDiabetes mellitus

    The study was suspended and during this time recruitment and study activities were halted. The study was ultimately terminated in April 2026 without having re-opened for recruitment additional participants.

  • NCT01799057TerminatedInsulin resistance

    The trial has been terminated due to difficulties with recruitment.

  • NCT03380091TerminatedInsulin resistance

    Recruitment challenges

40 of 43

Who is developing metformin?

3 companies: AstraZeneca, Nabiqasim Industries (Pvt) and Johnson & Johnson Private.

Companies
  • AstraZenecaPhase 4type 2 diabetes, chronic kidney disease
  • Nabiqasim Industries (Pvt)Phase 4diabetes mellitus, type 2 DM
  • Johnson & Johnson PrivatePhase 4diabetes mellitus

Trial sponsors

Funding

207 grants since 2016

National Institute on Aging$72.9MNational Institute of Diabetes and Digestive and Kidney Diseases$20.8MNational Heart, Lung, and Blood Institute$20.9M

Latest

See all 2,747 papers on metformin